Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention

Journal of the National Cancer Institute

Volumn 98, Issue 20, 2006, Pages 1494-1500

  Barry, Elizabeth L R ^a   Baron, John A ^a   Bhat, Shubha ^b   Grau, Maria V ^a   Burke, Carol A ^c   Sandler, Robert S ^d   Ahnen, Dennis J ^e   Haile, Robert W ^f   O'Brien, Thomas G ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DNA; FOLIC ACID; ORNITHINE DECARBOXYLASE; PLACEBO;

ADULT; ARTICLE; CANCER RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC MARKER; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; AGED; ALANINE; ANTICARCINOGENIC AGENTS; ASPIRIN; COLORECTAL NEOPLASMS; CONTINENTAL POPULATION GROUPS; FEMALE; FOLIC ACID; GASTROINTESTINAL AGENTS; GENE FREQUENCY; GENOTYPE; GLYCINE; HUMANS; MALE; MIDDLE AGED; ORNITHINE DECARBOXYLASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 33750205691     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj398     Document Type: Article

References (23)

1. Gerner EW, Meyskens FL Jr. Polyamines and cancer: Old molecules, new understanding. Nat Rev Cancer 2004;4:781-92.
2. Pegg AE, Shantz LM, Coleman CS. Ornithine decarboxylase: Structure, function and translational regulation. Biochem Soc Trans 1994;22: 846-52.
3. Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA Jr. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 1997;57:199-201.
4. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281: 1509-12.
5. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A 1993;90:7804-8.
6. Fultz KE, Gerner EW. APC-dependent regulation of ornithine decarboxylase in human colon tumor cells. Mol Carcinog 2002;34:10-8.
7. Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillen-Rodriguez JM, et al. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis 1999;20:1709-13.
8. Ignatenko NA, Babbar N, Mehta D, Casero RA Jr, Gerner EW. Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol Carcinog 2004;39:91-102.
9. Babbar N, Ignatenko NA, Casero RA Jr, Gerner EW. Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem 2003;278:47762-75.
10. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A 2003;100:7859-64.
11. Walhout AJ, van der Vliet PC, Timmers HT. Sequences flanking the E-box contribute to cooperative binding by c-Myc/Max heterodimers to adjacent binding sites. Biochim Biophys Acta 1998;1397:189-201.
12. Guo Y, Harris RB, Rosson D, Boorman D, O'Brien TG. Functional analysis of human ornithine decarboxylase alleles. Cancer Res 2000;60:6314-7.
13. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
14. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: Case-control studies with no controls! Am J Epidemiol 1996;144:207-13.
15. Visvanathan K, Helzlsouer KJ, Boorman DW, Strickland PT, Hoffman SC, Comstock GW, et al. Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk. J Urol 2004;171:652-5.
16. O'Brien TG, Guo Y, Visvanathan K, Sciulli J, McLaine M, Helzlsouer KJ, et al. Differences in ornithine decarboxylase and androgen receptor allele frequencies among ethnic groups. Mol Carcinog 2004;41:120-3.
17. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
18. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001;61:3566-9.
19. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst 2005;97:457-60.
20. Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, Goode EL, et al. Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2004;13:889-93.
21. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005;14:616-9.
22. Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2006;15:502-8.
23. McGreavey LE, Turner F, Smith G, Boylan K, Timothy Bishop D, Forman D, et al. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics 2005;15:713-21.